Aristides Capital’s ClearPoint Neuro CLPT Stock Holding History

Aristides Capital’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22,882	Closed	-$257K	–	206
2021 Q4	$257K	Buy	+22,882	New	+$343K	0.12%	174

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aristides Capital's CLPT Position: Q1 2022 in Review

Aristides Capital sold out of ClearPoint Neuro (CLPT) in Q1 2022, closing a stake of 22,882 shares — an estimated $257K sold.

Aristides Capital first reported a position in CLPT in Q4 2021 and held it in 1 quarter. The position peaked at $257K in Q4 2021. 64 funds tracked by Wall St. Rank hold CLPT as of Q1 2022.

Aristides Capital reported no remaining ClearPoint Neuro position as of Q1 2022 after selling out during the quarter.
Aristides Capital sold 22,882 ClearPoint Neuro shares in Q1 2022, an estimated $257K.
Aristides Capital first reported a position in ClearPoint Neuro in Q4 2021 and held it in 1 quarter.
Aristides Capital's ClearPoint Neuro position peaked at $257K in Q4 2021.
64 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.